ArticleInflammation2026
Disturbed LTB4 Metabolism in ILC2s Aggravates Ulcerative Colitis via Intercellular ATP Accumulation.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ulcerative colitis (UC), an inflammatory bowel disease of unknown etiology, has mucosal healing as its primary therapeutic goal. Innate lymphoid cells (ILCs) are crucial for orchestrating the balance between intestinal epithelial injury and repair in this process. However, the metabolic reprogramming and underlying mechanisms of ILCs during UC remain incompletely understood. ILC2s play a crucial role in promoting epithelial repair. This is controlled via eicosanoid metabolism, specifically by the synthesis of leukotriene B4 (LTB4). Additionally, the LTB4 synthesis reaction is the most significant reaction involved in ILCs in UC. We establish that ILC2s regulate their mitochondrial function through autocrine secretion of LTB4, which suppresses detrimental excessive ATP production and consequently maintains cellular homeostasis. This study reveals, at the single-cell level, metabolic reprogramming in ILCs and demonstrates that eicosanoid metabolism – one of the most significant metabolic alterations – sustains the anti-inflammatory function of ILC2s, identifying a novel therapeutic target for promoting mucosal repair in colitis. Clinical trial number: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.